| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Laboratory of Genetics, National Institute of Mental Health (T.B.U., J.H.), Basic Neurosciences Program, National Institute of Neurological Diseases and Stroke (T.V., G.H., E.M.), National Institutes of Health, Bethesda, Maryland 20892; and Endocrine Unit (G.S.), Massachusetts General Hospital, Boston, Massachusetts 02114
Address all correspondence and requests for reprints to: Ted Usdin, Laboratory of Genetics, NIMH, Building 36/Room 3D06, 36 Convent Drive MSC4094, Bethesda, Maryland 20892-4094. E-mail: usdin{at}codon.nih.gov
The PTH2 receptor is a G protein-coupled receptor selectively activated by PTH. We are studying the receptors distribution to guide the investigation of its physiological function. We have now generated an antibody from a C-terminal peptide sequence of the PTH2 receptor and used this to study its cellular distribution. Labeling with the antibody identified a number of endocrine cells expressing the PTH2 receptor, including thyroid parafollicular cells, pancreatic islet D cells, and some gastrointestinal peptide synthesizing cells. There was complete overlap of PTH2 receptor labeling with somatostatin in pancreatic islets, and partial overlap with somatostatin in thyroid parafollicular cells and in the gastrointestinal tract. Furthermore, observations made previously by in situ hybridization histochemistry, including expression throughout the cardiovascular system, as well as by discrete populations of cells within the gastrointestinal tract and reproductive system were confirmed. These data suggest a broad role for the PTH2 receptor, especially within the endocrine system, and provide a basis for experimental exploration of its physiology.
This article has been cited by other articles:
![]() |
T. B. Usdin, M. Paciga, T. Riordan, J. Kuo, A. Parmelee, G. Petukova, R. D. Camerini-Otero, and E. Mezey Tuberoinfundibular Peptide of 39 Residues Is Required for Germ Cell Development Endocrinology, September 1, 2008; 149(9): 4292 - 4300. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Verhoeven and K. De Gendt Tuberoinfundibular Peptide of 39 Residues: A Neuromodulator Starting a Second Career in the Control of Meiosis Endocrinology, September 1, 2008; 149(9): 4289 - 4291. [Full Text] [PDF] |
||||
![]() |
T. M. Murray, L. G. Rao, P. Divieti, and F. R. Bringhurst Parathyroid Hormone Secretion and Action: Evidence for Discrete Receptors for the Carboxyl-Terminal Region and Related Biological Actions of Carboxyl- Terminal Ligands Endocr. Rev., February 1, 2005; 26(1): 78 - 113. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Papasani, R. C. Gensure, Y.-L. Yan, Y. Gunes, J. H. Postlethwait, B. Ponugoti, M. R. John, H. Juppner, and D. A. Rubin Identification and Characterization of the Zebrafish and Fugu Genes Encoding Tuberoinfundibular Peptide 39 Endocrinology, November 1, 2004; 145(11): 5294 - 5304. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Miao, B. He, B. Lanske, X.-Y. Bai, X.-K. Tong, G. N. Hendy, D. Goltzman, and A. C. Karaplis Skeletal Abnormalities in Pth-Null Mice Are Influenced by Dietary Calcium Endocrinology, April 1, 2004; 145(4): 2046 - 2053. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Sugimura, T. Murase, S. Ishizaki, K. Tachikawa, H. Arima, Y. Miura, T. B. Usdin, and Y. Oiso Centrally Administered Tuberoinfundibular Peptide of 39 Residues Inhibits Arginine Vasopressin Release in Conscious Rats Endocrinology, July 1, 2003; 144(7): 2791 - 2796. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Eichinger, N. Fiaschi-Taesch, T. Massfelder, S. Fritsch, M. Barthelmebs, and J.-J. Helwig Transcript Expression of the Tuberoinfundibular Peptide (TIP)39/PTH2 Receptor System and Non-PTH1 Receptor-Mediated Tonic Effects of TIP39 and Other PTH2 Receptor Ligands in Renal Vessels Endocrinology, August 1, 2002; 143(8): 3036 - 3043. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Dobolyi, H. Ueda, H. Uchida, M. Palkovits, and T. B. Usdin Anatomical and physiological evidence for involvement of tuberoinfundibular peptide of 39 residues in nociception PNAS, January 24, 2002; (2002) 42416199. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. L. Ward, C. J. Small, K. G. Murphy, A. R. Kennedy, M. A. Ghatei, and S. R. Bloom The Actions of Tuberoinfundibular Peptide on the Hypothalamo-Pituitary Axes Endocrinology, August 1, 2001; 142(8): 3451 - 3456. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Piserchio, T. Usdin, and D. F. Mierke Structure of Tuberoinfundibular Peptide of 39 Residues J. Biol. Chem., August 25, 2000; 275(35): 27284 - 27290. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. J. Hoare, J. A. Clark, and T. B. Usdin Molecular Determinants of Tuberoinfundibular Peptide of 39 Residues (TIP39) Selectivity for the Parathyroid Hormone-2 (PTH2) Receptor. N-TERMINAL TRUNCATION OF TIP39 REVERSES PTH2 RECEPTOR/PTH1 RECEPTOR BINDING SELECTIVITY J. Biol. Chem., August 25, 2000; 275(35): 27274 - 27283. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Dobolyi, H. Ueda, H. Uchida, M. Palkovits, and T. B. Usdin Anatomical and physiological evidence for involvement of tuberoinfundibular peptide of 39 residues in nociception PNAS, February 5, 2002; 99(3): 1651 - 1656. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |